Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Parkinson's Disease

    Atlanta, GA

    Search
    Parkinson's Disease
    Atlanta, GA
    Show Map
    Map View
    Atlanta, GA
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      38 Parkinson's Disease Trials near Atlanta, GA

      Power is an online platform that helps thousands of Parkinson's Disease patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Apomorphine Infusion for Parkinson's Disease

      Atlanta, Georgia
      This is a Phase 3, multicenter, open-label, safety and tolerability study of continuous apomorphine infusion in subjects with advanced Parkinson's Disease (PD) whose motor fluctuations remain unsatisfactory with levodopa (or levodopa/carbidopa) and at least one other class of drugs or mode of therapy for PD.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:30+

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      99 Participants Needed

      BHV-8000 for Parkinson's Disease

      Atlanta, Georgia
      A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3
      Age:40 - 85

      Key Eligibility Criteria

      Disqualifiers:Other Parkinsonian Syndromes, CNS Disease, Smokers, Others
      Must Not Be Taking:PD Medications

      550 Participants Needed

      Mirabegron + Behavioral Therapy for Parkinson's Disease

      Decatur, Georgia
      The purpose of this study is to learn about different treatments for overactive bladder symptoms in Parkinson's Disease. The investigators want to find out if people who do not respond to one treatment (either behavioral or drug treatment) will respond to combined treatment. The investigators also want to find out what factors influence whether someone responds to the treatments.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Cognitive Impairment, Depression, Diabetes, Others
      Must Not Be Taking:Bladder Relaxants

      146 Participants Needed

      Deep Brain Stimulation for Parkinson's Disease

      Atlanta, Georgia
      Patients with Parkinson's Disease will be studied before, during, and after a deep brain stimulation implantation procedure to see if the stimulation location and the size of the electrical field produced by subthalamic nucleus (STN) DBS determine the degree to which DBS engages circuits that involve prefrontal cortex executive functions, and therefore have a direct impact on the patient's ability to inhibit actions.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:45 - 75

      Key Eligibility Criteria

      Disqualifiers:Severe Tremor, Dementia, Heart Disease, Others
      Must Not Be Taking:Psychotropic Medications

      80 Participants Needed

      Zoledronic Acid for Parkinson's Disease

      Atlanta, Georgia
      This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 2650 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4
      Age:60+

      Key Eligibility Criteria

      Disqualifiers:Hip Fracture, Non-ambulatory, Kidney Dialysis, Others
      Must Not Be Taking:Bisphosphonates, SERMs, Denosumab

      2650 Participants Needed

      NEU-411 for Parkinson's Disease

      Atlanta, Georgia
      The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway. Participants will: • Take NEU-411 or placebo every day for 52 weeks

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:40 - 80

      Key Eligibility Criteria

      Disqualifiers:Secondary Parkinsonian Syndromes, Uncontrolled Diabetes, Others

      150 Participants Needed

      BIA 28-6156 for Parkinson's Disease

      Atlanta, Georgia
      This trial is testing a new drug called BIA 28-6156 to see if it can slow down movement problems in people with Parkinson's disease who have a specific genetic mutation. The study will compare the drug to another treatment over a period of several months.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:35 - 80

      Key Eligibility Criteria

      Disqualifiers:Gaucher's Disease, LRRK2 Variant, Others
      Must Be Taking:PD Medications

      237 Participants Needed

      Lenrispodun for Parkinson's Disease

      Decatur, Georgia
      This trial is testing a medication called Lenrispodun to help people with Parkinson's Disease. It aims to reduce symptoms that appear when their usual medication stops working and to control involuntary movements caused by their current treatment. The study involves an initial check-up, a phase where patients receive either Lenrispodun or another substance, and a later check-up to ensure safety.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:40 - 80

      Key Eligibility Criteria

      Disqualifiers:Late-stage PD, Dementia, Others
      Must Be Taking:Levodopa, MAO-B Inhibitors

      132 Participants Needed

      Gene Therapy for Parkinson's Disease

      Atlanta, Georgia
      The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:45 - 75

      Key Eligibility Criteria

      Disqualifiers:Vascular Disease, Cognitive Impairment, Psychosis, Others
      Must Be Taking:Antiparkinsonian

      87 Participants Needed

      ANPD001 for Parkinson's Disease

      Atlanta, Georgia
      This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease. All participants will have ANPD001 cells manufactured from their own previously collected cells.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 1
      Age:50 - 70

      Key Eligibility Criteria

      Disqualifiers:Cognitive Impairment, Epilepsy, Stroke, Others
      Must Be Taking:Levodopa

      9 Participants Needed

      Lu AF28996 for Parkinson's Disease

      Atlanta, Georgia
      This trial is testing a new drug called Lu AF28996 to see if it is safe and well-tolerated in people with Parkinson's disease. The study will check how the body processes the drug and if it causes any side effects. Participants will take the drug at different frequencies during the study.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:35 - 85

      Key Eligibility Criteria

      Disqualifiers:Neurological, Psychiatric, Seizure, Respiratory, Others
      Must Be Taking:Levodopa

      57 Participants Needed

      LY4006896 for Parkinson's Disease

      Decatur, Georgia
      The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:30 - 85

      Key Eligibility Criteria

      Disqualifiers:Neurological Disease, Unstable Illnesses, Allergies, Others
      Must Be Taking:Dopaminergic Therapy

      127 Participants Needed

      Gamma Sensory Flicker for Parkinson's Disease

      Atlanta, Georgia
      This study aims to answer the question: to assess the safety, and tolerability of gamma light in Parkinson's disease (PD) patients with freezing of gait (FOG). Parkinson's disease (PD) patients often experience a complex gait disorder known as Freezing of Gait (FOG). FOG is characterized by brief arrests of stepping when initiating gait, turning, and walking straight and patients describe it as their feet being "glued" to the floor. FOG in Parkinson's disease (PD) is a considerable public health burden worldwide. It is a poorly understood gait symptom that has potentially grave consequences as FOG is intermittent and unpredictable, a leading cause of falls with injury, and results in loss of independence. FOG is generally found to be associated with cognitive decline, particularly executive dysfunction which, in turn, has been associated with higher spinal fluid amyloid (Aβ42) levels in PD. There is data linking amyloid to FOG. A previous study showed that the gamma light helped reduce some amyloid. The research team is studying if gamma light exposure for 1 hour daily is well tolerated. Also, does it have any effect on freezing of gait severity?

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:50 - 80

      Key Eligibility Criteria

      Disqualifiers:Atypical Parkinsonism, Dementia, Major Depression, Others
      Must Be Taking:Levodopa

      28 Participants Needed

      Genetic Registry for Parkinson's Disease

      Atlanta, Georgia
      Development of a central repository for PD-related genomic data for future research.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting

      Key Eligibility Criteria

      Disqualifiers:Atypical Parkinsonian Disorders, Hematologic Malignancies, Others

      25000 Participants Needed

      High-Intensity Treadmill Exercise for Parkinson's Disease

      Atlanta, Georgia
      This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III score at 12 months among persons with early stage Parkinson disease. 370 participants will be randomly assigned to 2 groups: 1)60-65% HRmax or 2)80-85% HRmax 4 times per week. The primary objective is to test whether the progression of the signs of Parkinson's disease is attenuated at 12 months in among persons who have not initiated medication for Parkinson Disease (PD) when they perform high-intensity endurance treadmill exercise.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:40 - 80

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular, Metabolic, Renal, Others
      Must Not Be Taking:PD Medications, Neuroleptics, Psychotropics, Others

      370 Participants Needed

      Deep Brain Stimulation for Parkinson's Disease

      Atlanta, Georgia
      The purpose of this study is to measure the effects of non-regular temporal patterns of deep brain stimulation (DBS) on motor symptoms and neural activity in persons with Parkinson's disease (PD), essential tremor (ET), dystonia or multiple sclerosis (MS). These data will guide the design of novel stimulation patterns that may lead to more effective and reliable treatment with DBS. These data will also enable evaluation of current hypotheses on the mechanisms of action of DBS. Improving our understanding of the mechanisms of action of DBS may lead to full development of DBS as a treatment for Parkinson's disease and may lead to future applications of DBS.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased
      Age:21 - 80

      Key Eligibility Criteria

      Disqualifiers:Inability To Execute Motor Tasks, Others

      180 Participants Needed

      Gene Transfer for Pompe Disease

      Atlanta, Georgia
      This trial is testing a new treatment called SPK-3006 for adults with late-onset Pompe disease who are already on enzyme replacement therapy. The treatment involves an infusion that delivers a gene to help produce a missing enzyme. The goal is to see if this new approach is safe and effective.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Hepatitis, HIV, Liver Disease, Others
      Must Be Taking:Enzyme Replacement

      4 Participants Needed

      Exercise for Parkinson's Disease

      Decatur, Georgia
      Veterans with mid to later stage Parkinson's disease (PD) may not be able to work out as hard as they need to, to prevent brain cell loss. Maybe they could work out longer and more frequently to make up for this during their good times and good weeks and then rest during the bad weeks. The investigators will compare how effective working out a lot one week per month with a break of three weeks is to continuously exercising weekly with no breaks in people with mid stage PD. The investigators will look at how fast participants walk per minute, whether they become more physically active, the biochemicals in their blood, and at how stiff their blood vessels are before and after the exercise.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:40+

      Key Eligibility Criteria

      Disqualifiers:Major Depression, Stroke, Cardiac Disease, Others
      Must Be Taking:Antiparkinsonian Medications

      123 Participants Needed

      ND0612 for Parkinson's Disease

      Atlanta, Georgia
      This is a multi-center, randomized, double-blind, double-dummy, active controlled clinical Study. Following a screening period, eligible subjects will be enrolled to an open-label oral IR-LD/CD adjustment period; then an open-label ND0612 conversion period; then after optimization periods subjects will be randomized to receive either ND0612 or its matching Placebo with IR-LD/CD. Subjects can continue to an optional open-label extension period.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:30 - 80

      Key Eligibility Criteria

      Disqualifiers:Atypical Parkinsonism, Severe Dyskinesias, Others
      Must Be Taking:Levodopa

      381 Participants Needed

      UCB0022 for Parkinson's Disease

      Decatur, Georgia
      This trial is testing UCB0022, a new medication, to see if it can help people with advanced Parkinson's Disease. It is added to their regular treatments to see if it reduces the time they spend with bad symptoms. The goal is to make their usual treatments work better.
      Stay on current meds

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:35 - 85

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      207 Participants Needed

      Why Other Patients Applied

      "It seems my Parkinson’s is progressing more rapidly now. And my meds are lagging behind. My off time is more frequent and the episodes are longer. Trying to figure out what my options are."

      TM
      Parkinson's PatientAge: 58

      "I wasn’t diagnosed until February, but I showed symptoms over ten years before. I want to help find a cure. I have lost family members to Parkinson’s and want to contribute to the search for better treatments before my children possibly come down with it."

      YX
      Parkinson's PatientAge: 61

      "My dad was in a research group for Parkinson's for about 6 years, which was very interesting. I was just diagnosed 1.5 years ago, and started on low dose Sinemet. Doing well on Sinemet, but I'd like to get ahead of the condition. I'm excited about participating in research. "

      LN
      Parkinson's PatientAge: 74

      "I have 5 kids. I'll do anything I can to slow this disease down in hopes that I can stay active with them into their adulthood. I also feel I am serving the greater good for all those who suffer from Parkinson's. Since I'm self employed, my schedule is flexible. "

      UR
      Parkinson's PatientAge: 53

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58
      Match to a Parkinson's Disease Trial

      Dance Aerobics for Parkinson's Disease

      Decatur, Georgia
      Parkinson's disease (PD) is a difficult to treat condition that impairs mobility and thinking. It is not fully treated by drugs and surgery. Two priority issues for most people with PD are "OFF-time" and Cognitive impairment. Even under best medical management, 74% of people with PD experience "OFF-time," which is when medications are just not working right. OFF-time severely impacts both quality of life and thinking. Cognitive problems are found even in newly diagnosed people with PD and are very difficult to treat. However, the investigators' research has shown that partnered dance-aerobic exercise (PDAE) reduces OFF-time on the official test for OFF-time of the Movement Disorders Society, the Movement Disorders Society Unified Parkinson Disease Rating Scale-IV, (MDS-UPDRS-IV). PDAE improves other symptoms too. Benefits of the therapy have lasted for at least one-month after PDAE sessions stopped. PDAE provides aerobic exercise during an improvisational, cognitively-engaging physical activity. Cognitive engagement is a critical component of PDAE. Previous research showed PDAE improved spatial cognition, the ability to navigate, to mentally picture shapes and paths in the mind and to know the relationships between objects, people and places. Also, the investigators showed with imaging of the brain using a magnet in a scanner that twice weekly PDAE training increases activity in brain regions used in thinking and decision making. The investigators know that exercise benefits mobility and cognitive problems. The investigators even think exercise might protect brain cells in people with PD. But no one has really been able to show with biomarkers that exercise is protective of brain cells in humans.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:40 - 89

      Key Eligibility Criteria

      Disqualifiers:Major Depression, Stroke, Cardiac Disease, Others
      Must Be Taking:Antiparkinsonian Medications

      82 Participants Needed

      Suvecaltamide for Tremors in Parkinson's Disease

      Atlanta, Georgia
      This trial tests suvecaltamide, a medication aimed at reducing severe tremors in adults with Parkinson's disease whose current treatments are not effective. The medication likely helps by calming the overactive nerves or muscles responsible for the tremors.

      Trial Details

      Trial Status:Recruiting
      Age:40 - 85

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      160 Participants Needed

      Immunotherapy vs Chemotherapy for Endometrial Cancer

      Atlanta, Georgia
      The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma who have not previously been treated with prior systemic chemotherapy. The primary study hypotheses are that pembrolizumab is superior to the combination of carboplatin and paclitaxel with respect to Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and Overall Survival (OS).
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Immunodeficiency, Active Infection, Autoimmune, Others
      Must Not Be Taking:Immunosuppressants, Steroids, Anti-PD-1

      280 Participants Needed

      Pembrolizumab + ADT for Prostate Cancer

      Atlanta, Georgia
      This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus Androgen Deprivation Therapy (ADT) versus placebo plus enzalutamide plus ADT in participants with mHSPC. The primary hypothesis is that in participants with mHSPC, the combination of pembrolizumab plus enzalutamide plus ADT is superior to placebo plus enzalutamide plus ADT with respect to 1) radiographic progression-free survival (rPFS) per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR) and 2) overall survival (OS). As of 19-JAN-2023, the study was unblinded and all study participants stopped ongoing treatment with pembrolizumab/placebo and will continue to receive Standard of Care treatment until meeting protocol-specified discontinuation criteria if deriving clinical benefit. Safety analysis will be performed at the end of the study; there will be no further analyses for efficacy and electronic patient-reported outcome (ePRO) endpoints collected from participants beyond the IA1 cutoff date. All study participants will stop ongoing treatment with pembrolizumab/placebo. Exceptions may be requested for study participants who, in the assessment of their study physician, are benefitting from the combination of enzalutamide and pembrolizumab, after consulting with the Sponsor. All other study participants should be discontinued from study and be offered standard of care (SOC) treatment as deemed necessary by the Investigator. If enzalutamide as SOC is not accessible off study to the participant, central sourcing may continue. As of Amendment 04, disease progression will no longer be centrally verified, participants will only be assessed locally. As of Amendment 4, Second Course treatment is not an option for participants. There are currently no participants in the Second Course Phase.
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Active Malignancy, Autoimmune Disease, Immunodeficiency, Others
      Must Be Taking:Androgen Deprivation Therapy

      1251 Participants Needed

      Pembrolizumab + BCG for Bladder Cancer

      Atlanta, Georgia
      Researchers are looking for new ways to treat high-risk non muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the bladder. High-risk means NMIBC may have a high chance of getting worse or coming back after treatment. The goals of this study are to learn: 1. If more people who receive pembrolizumab with Bacillus Calmette-Guerin (BCG) have no signs of cancer in their body and live longer without the cancer growing, spreading, or coming back compared to people who receive BCG alone. 2. About the safety and how well people tolerate BCG alone or in combination with pembrolizumab.
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Metastatic UC, Active Autoimmune, Others
      Must Be Taking:BCG

      1397 Participants Needed

      Pembrolizumab for High-risk Stage II Melanoma

      Atlanta, Georgia
      This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma. Participants in Part 1 will receive either pembrolizumab or placebo in a double-blind design every 3 weeks (Q3W) for up to 17 cycles/\~1 year (each cycle = 21 days). Participants who complete the initial treatment of 17 cycles of pembrolizumab in Part 1 and experience disease recurrence may be eligible for re-challenge with pembrolizumab at the same dose and schedule of 200 mg Q3W (21-day cycles) for up to 35 cycles (up to \~2 years) in Part 2 in an open label design. Participants who complete the initial treatment of placebo and experience disease recurrence may be eligible to switch over to pembrolizumab 200 mg Q3W (21-day cycles) for up to 35 cycles (up to \~2 years) in Part 2 in an open label design. The primary hypothesis of this study is that pembrolizumab increases recurrence-free survival (RFS) compared to placebo. Per protocol, response/ progression or adverse events (AEs) during re-challenge/switch-over in Part 2 will not be counted towards the RFS outcome measure or safety outcome measures respectively.
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Immunodeficiency, Autoimmune, HIV, Others
      Must Not Be Taking:Immunosuppressants, Steroids, Antineoplastics, Others

      976 Participants Needed

      Drug Combinations for Kidney Cancer

      Atlanta, Georgia
      The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Cardiac Disease, Others
      Must Not Be Taking:Steroids, Immunosuppressants, Others

      1653 Participants Needed

      Chemotherapy + Pembrolizumab/Olaparib for Ovarian Cancer

      Atlanta, Georgia
      The purpose of this study is to assess the efficacy and safety of treatment with carboplatin/paclitaxel\* PLUS pembrolizumab (MK-3475) and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary peritoneal cancer. The primary study hypotheses are that the combination of pembrolizumab plus carboplatin/paclitaxel\* followed by continued pembrolizumab and maintenance olaparib is superior to carboplatin/paclitaxel alone with respect to Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in participants with programmed death-ligand 1 (PD-L1) positive tumors (Combined Positive Score \[CPS\]≥10) and in all participants, and that the combination of pembrolizumab plus carboplatin/paclitaxel followed by continued pembrolizumab is superior to carboplatin/paclitaxel alone with respect to PFS per RECIST 1.1 in participants with PD-L1 positive tumors (CPS≥10) and in all participants.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:BRCA Mutation, Pneumonitis, Autoimmune Disease, Others
      Must Not Be Taking:CYP3A4 Inhibitors, CYP3A4 Inducers

      1367 Participants Needed

      Pembrolizumab + Chemotherapy/Radiotherapy for Endometrial Cancer

      Atlanta, Georgia
      The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to overall survival (OS). The primary hypotheses are that pembrolizumab + adjuvant chemotherapy is superior to placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to DFS as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to OS.
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Recurrent Cancer, Autoimmune Disease, HIV, Others
      Must Not Be Taking:Immunosuppressants, Steroids, PD-1 Inhibitors

      990 Participants Needed

      Pembrolizumab Combinations for Small Cell Lung Cancer

      Atlanta, Georgia
      This trial tests a combination of pembrolizumab and new experimental drugs in patients with advanced lung cancer who did not respond to previous treatments. The goal is to see if this combination is safe and effective. Pembrolizumab helps the immune system attack cancer by blocking a protein that stops immune cells from working. Pembrolizumab has been widely studied and approved for the treatment of various cancers, including lung cancer.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Active CNS Metastases, Autoimmune Disease, Others
      Must Not Be Taking:RTK Inhibitors, Anti-CTLA-4

      110 Participants Needed

      12

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Parkinson's Disease clinical trials in Atlanta, GA pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Parkinson's Disease clinical trials in Atlanta, GA work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Parkinson's Disease trials in Atlanta, GA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Atlanta, GA for Parkinson's Disease is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Atlanta, GA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Parkinson's Disease medical study in Atlanta, GA?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Parkinson's Disease clinical trials in Atlanta, GA?

      Most recently, we added Mirabegron + Behavioral Therapy for Parkinson's Disease, BHV-8000 for Parkinson's Disease and LY4006896 for Parkinson's Disease to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials in Georgia

      Anxiety Clinical Trials in Georgia

      Schizophrenia Clinical Trials in Georgia

      ADHD Clinical Trials in Georgia

      Bipolar Disorder Clinical Trials in Georgia

      Multiple Sclerosis Clinical Trials in Georgia

      Autism Clinical Trials in Georgia

      Treatment Resistant Depression Clinical Trials in Georgia

      Borderline Personality Disorder Clinical Trials in Georgia

      Social Anxiety Disorder Clinical Trials in Georgia

      Parkinson's Disease Clinical Trials in Georgia

      Alzheimer's Disease Clinical Trials in Georgia

      By Location

      Clinical Trials near Atlanta, GA

      Clinical Trials near Augusta, GA

      Clinical Trials near Decatur, GA

      Clinical Trials near Savannah, GA

      Clinical Trials near Marietta, GA

      Clinical Trials near Columbus, GA

      Clinical Trials near Macon, GA

      Clinical Trials near Lawrenceville, GA

      Clinical Trials near Gainesville, GA

      Clinical Trials near Athens, GA

      Clinical Trials near Roswell, GA

      Clinical Trials near Stockbridge, GA

      Other People Viewed

      By Subject

      59 Alzheimer's Disease Trials near Atlanta, GA

      31 Schizophrenia Trials near Atlanta, GA

      39 Parkinson's Disease Trials near Tampa, FL

      31 Psoriasis Trials near Atlanta, GA

      68 Depression Trials near Atlanta, GA

      24 Bipolar Disorder Trials near Atlanta, GA

      49 Parkinson's Disease Trials near Austin, TX

      17 Alzheimer's Disease Trials near High Point, NC

      42 Clinical Trials near Montana

      Top Clinical Trials near Atlanta, GA

      Top Clinical Trials near Atlanta, GA

      Top Diabetes Clinical Trials near Atlanta, GA

      By Trial

      Deep Brain Stimulation for Parkinson's Disease

      TMS + Gait Training for Parkinson's Disease

      CereGate Therapy for Freezing of Gait in PD

      Smartshoes for Parkinson's Disease

      Brain Activity Study for Cognitive Impairment in Parkinson's Disease

      Brain Stimulation for Parkinson's Disease

      DBS Surgery for Parkinson's Disease

      Deep Brain Stimulation for Parkinson's Disease

      Deep Brain Stimulation for Parkinson's Disease

      Pembrolizumab + Chemotherapy/Radiotherapy for Endometrial Cancer

      Drug Combinations for Kidney Cancer

      Pembrolizumab + Olaparib for Squamous Cell Carcinoma of the Lung

      Related Searches

      Top Parkinsons-disease Clinical Trials near Austin, TX

      Top Parkinsons-disease Clinical Trials near Boston, MA

      Top Parkinsons-disease Clinical Trials near Columbus, OH

      Top Parkinsons-disease Clinical Trials near Denver, CO

      Top Parkinsons-disease Clinical Trials near Tampa, FL

      Top Psoriasis Clinical Trials near Atlanta, GA

      Nitrous Oxide for Suicidal Thoughts

      Ketamine-Enhanced Psychotherapy for PTSD

      Combination Therapy for Non-Hodgkin's Lymphoma

      TEV-56286 for Multiple System Atrophy

      Brain Imaging Biomarkers for Brain Metastases

      Factors Influencing Migraine in Adolescents